Skip to main content
. Author manuscript; available in PMC: 2009 Jul 28.
Published in final edited form as: Vaccine. 2008 Jun 2;26(32):4041–4047. doi: 10.1016/j.vaccine.2008.05.023

Figure 3.

Figure 3

Inhibition of post AVA vaccination serum binding to PA in an antigen-specific ELISA. PA63 is a proteolytic fragment of PA83. Domain 4 (D4) and PA20 fragments were expressed as GFP fusion proteins. All inhibitors were present at approximately 150 fold excess of antibody, and in equal molar concentrations. Values for PA63, PA20, and D4 are expressed as the percentage of PA83-inhibitable binding. For each inhibitor, X indicates the mean values for the 11 donors.